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In this issue of Clinical Cancer Research, evidence is pro-
vided on how to avoid cardiotoxicity when targeting hERG
Kþ channel for cancer therapy. hERG regulates different
aspects of neoplastic progression. Although its blockade has
effective anticancer effects in experimental models, it may
lead to fatal arrhythmias in humans. Clin Cancer Res; 23(1); 3–5.
2016 AACR.
See related article by Pointer et al., p. 73
In this issue of Clinical Cancer Research, Pointer and colleagues
analyze the expression of Ether-a-go-go–related gene (hERG) Kþ
channels, in cells derived from glioblastoma patients (GPDC), in
GPDC-derived in vivo xenografts, and in a clinically annotated
human glioblastoma tissue microarray (1). hERG expression
in glioblastoma xenografts correlates with higher proliferative
indices. Moreover, tissue microarray analysis shows that in
patients with glioblastomas that displayed high hERG expression,
survival was generally shorter. Consistent with these results, the
GPDCs with high hERG expression showed a reduction in neuro-
sphere formation when treated with hERG inhibitors. Finally, a
retrospective analysis was carried out on patients who had
received drugs known to exert off-target hERG blockade for the
treatment of different comorbidities. These patients displayed a
significantly better survival rate compared with the patients who
were not treated with such drugs. Subgroup analysis shows that
survival was prolonged in patients affected by glioblastomas with
high hERG expression, whereas no such effect was produced by
hERG blockers in patients affected by glioblastomas with low
hERG expression. Overall, these data suggest that hERG is a
potentialmarker of survival in glioblastoma.Moreover, common-
ly prescribed hERG inhibitors devoid of proarrhythmic activity
could be used as adjuvant therapeutic agents for glioblastoma.
hERG channels are voltage-dependent Kþ channels that are
physiologically expressed in cardiac myocytes, neurons, smooth
muscle of different organs, and neuroendocrine cells (2). In
cardiac cells, hERG is thought to be the molecular correlate of
IKr, a K
þ current that contributes to action potential repolarization
(3). However, evidence has been accumulating in the past two
decades showing that hERG is often aberrantly expressed in
neoplastic cell lines (4) and primary human cancers, such as
glioma, neural crest–derived tumors (neuroblastoma and mela-
noma), and a variety of carcinomas and leukemias (4). Cellular
and molecular studies have demonstrated that hERG regulates
different aspects of neoplastic progression (Fig. 1): cell prolifer-
ation and survival, secretion of proangiogenic factors, invasive-
ness, and metastasis (4, 5). Such pleiotropic effects are not
necessarily the same, even in closely related cancers. For example,
hERG mainly regulates cell survival in lymphoid leukemia, but
transendothelial migration in myeloid leukemia. In solid tumors
such as colorectal and gastric cancer, it was found to affect
neoangiogenesis and themetastatic process (for review, see ref. 6).
What is particularly important in the present context is that
growing evidence indicates that blocking hERGhas antineoplastic
effects also in vivo. Such preclinical evidence would strongly
encourage the consideration of hERG as a possible target for
antineoplastic therapy, if many hERG inhibitors did not produce
cardiotoxic effects in humans. As is well-known, inhibiting hERG
can cause serious cardiac arrhythmias by retarding cardiac repo-
larization. This is reflected in a longer electrocardiographic QT
interval, which can give rise to torsade de pointes, a ventricular
arrhythmia that may lead to ventricular fibrillation (7). In par-
ticular, fatal arrhythmias can be caused by class III antiarrhythmic
drugs, which comprise many widely used hERG blockers, such as
E4031;Way 123, 398; anddofetilide. Therefore, hERG is generally
considered an undesirable pharmacologic target (8). However,
the structural features of the channel pore make hERG rather
promiscuous, in that it can interact with many structurally dif-
ferent compounds. A number of thesemolecules, commonly used
in the clinical setting, effectively block hERG channels without
facilitating arrhythmia (9). Among these "nontorsadogenic"
hERG blockers are the antiepileptic phenytoin, the antipsychotics
fluoxetine and sertindole, the antiestrogen tamoxifen, the anti-
hypertensive verapamil, and the macrolide antibiotics (9). Some
of these drugs were also considered in the clinical study by Pointer
and colleagues (1). Because of the current mechanistic uncertain-
ties about the pathophysiologic link between QT prolongation
and arrhythmia, it is unclear what the likelihood would be of a
given hERG inhibitor producing a torsadogenic effect. One pos-
sibility that is gaining increasing recognition is that blocking
hERG alone is not sufficient to cause arrhythmia, and the torsa-
dogenic potential of a given compound depends on the full
spectrum of ion channels it is able to modulate (10).
In this light, one can hypothesize different possible pharma-
cologic approaches to exploit the anticancer effects of hERG
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blockade while avoiding cardiotoxicity (Fig. 1). The simplest
possibility is using nontorsadogenic hERG blockers in clinical
trials. The article by Pointer and colleagues (1) is the first dem-
onstration that such a strategy can be effective in humans. More-
over, one has the option of choosing a treatment for tumor
comorbidities, which also targets hERG. As suggested by the
authors, the hERG blocker fluoxetine (Prozac; Eli Lilly) could be
preferentially used to treat the cancer-relateddepression.Wepoint
out that another class of nontorsadogenic hERG blockers is
constituted by macrolide antibiotics, which were found to have
hERG-dependent antileukemic effects in preclinical studies (11).
These could be included as standard antimicrobial agents in acute
leukemia induction schedules. In fact, ongoing clinical trials are
testing clarithromycin for the treatment ofmultiplemyeloma and
lymphoma (https://ClinicalTrials.gov/). In general, we believe it
would be extremely fruitful to extend the pharmacologic studies
on nontorsadogenic hERG blockers to better define the concen-
tration ranges that may allow effective treatment of both neopla-
sia and the comorbidity.
Another possible therapeutic strategy is seeking to target the
tumor-specific hERG features. Three hERG genes have been iden-
tified to date: hERG1, hERG2, and hERG3 (2). In turn, hERG1 has
two isoforms: hERG1a and hERG1b. The vast majority of non-
neuronal tissues and cancers tend to express hERG1A. However,
leukemias preferentially express the other isoform, that is,
hERG1B. On the basis of this observation, Gasparoli and collea-
gues (12) developed apyrimidoindole derivative that showsmore
selective inhibition of hERG1B. This drug could represent a first-
in-class compound to develop isoform-specific hERG blockers.
A further tumor-specific feature of hERG channels is that, in
neoplastic tissue, they tend to associate with membrane proteins
different from the classical accessory b subunits, which are the
typical hERG partners in cardiac cells (7). A common molecular
partner of hERG1 in tumor cells is the b1 subunit of integrin
receptors (4). Hence, specific molecular tools, such as bifunction-
al antibodies, could be produced to disrupt the hERG/b1 complex
in cancer cells, thus sparing the cardiac hERG channels.
These possible approaches are encouraged by the retrospective
analysis carried out by Pointer and colleagues (1), which gives, for
thefirst time, clinical potential to the possibility of targeting hERG
channels for anticancer therapy.
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Figure 1.
Left, hERG is often overexpressed on the plasma membrane of different human cancer cells. It regulates tumor cell proliferation, survival, migration/invasiveness,
and neoangiogenesis. Right, inhibiting hERG in different types of cancer cells (red lightning bolts) by using selective blockers that do not produce cardiac arrhythmia (as
indicated by the black cross) is a possible strategy for anticancer therapy. The article by Pointer and colleagues (1) suggests that this is feasible in glioblastoma.
Such a strategy may be effective in other cancers (shown in gray) in which hERG is overexpressed and has been shown to regulate neoplastic progression.
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